T1	tradename 0 8	ABRAXANE
T3	activeingredient 37 47	paclitaxel
T5	tradename 170 178	ABRAXANE
T7	tradename 242 262	ABRAXANE.  ABRAXANE
T9	nanoparticle 291 325	paclitaxel protein-bound particles
T11	corecomposition 354 367	albumin-bound
T13	fdaapprovaldate 393 397	2005
T15	tradename 501 509	ABRAXANE
T17	activeingredient 786 796	PACLITAXEL
T19	tradename 1074 1082	ABRAXANE
T21	chemoclass 1088 1109	microtubule inhibitor
T23	indication 1142 1166	Metastatic breast cancer
T25	indication 1402 1447	metastatic non-small cell lung cancer (NSCLC)
T27	tradename 1591 1591	
T29	indication 1591 1632	Metastatic adenocarcinoma of the pancreas
T31	tradename 1773 1773	
T33	indication 1773 1798	Metastatic Breast Cancer:
T35	tradename 1821 1829	ABRAXANE
T37	dose 1833 1842	260 mg/m2
T39	routeofadministration 1843 1856	intravenously
T41	tradename 1895 1895	
T43	indication 1895 1922	Non-Small Cell Lung Cancer:
T45	tradename 1945 1953	ABRAXANE
T47	dose 1957 1966	100 mg/m2
T49	routeofadministration 1967 1980	intravenously
T51	tradename 2111 2120	ABRAXANE.
T53	tradename 2128 2128	
T55	indication 2128 2159	Adenocarcinoma of the Pancreas:
T57	tradename 2182 2190	ABRAXANE
T59	dose 2194 2203	125 mg/m2
T61	routeofadministration 2204 2217	intravenously
T63	tradename 2361 2370	ABRAXANE.
T65	tradename 2396 2404	ABRAXANE
T67	tradename 2488 2496	ABRAXANE
T69	indication 2514 2555	metastatic adenocarcinoma of the pancreas
T71	indication 2629 2670	metastatic adenocarcinoma of the pancreas
T73	activeingredient 3230 3240	paclitaxel
T75	corecomposition 3255 3268	albumin-bound
T77	tradename 3498 3507	ABRAXANE.
T79	tradename 3589 3597	ABRAXANE
T81	tradename 3872 3880	ABRAXANE
T83	tradename 3924 3932	ABRAXANE
T85	tradename 4129 4137	ABRAXANE
T87	tradename 4210 4218	ABRAXANE
T89	activeingredient 4385 4395	paclitaxel
T91	tradename 4492 4500	ABRAXANE
T93	tradename 4745 4754	ABRAXANE.
T95	tradename 4810 4819	ABRAXANE.
T97	indication 4959 4983	metastatic breast cancer
T99	adversereaction 4988 4996	alopecia
T101	adversereaction 4998 5009	neutropenia
T103	adversereaction 5011 5029	sensory neuropathy
T105	adversereaction 5031 5043	abnormal ECG
T107	adversereaction 5045 5061	fatigue/asthenia
T109	adversereaction 5063 5081	myalgia/arthralgia
T111	adversereaction 5083 5096	AST elevation
T113	adversereaction 5098 5128	alkaline phosphatase elevation
T115	adversereaction 5130 5136	anemia
T117	adversereaction 5138 5144	nausea
T119	adversereaction 5146 5156	infections
T121	adversereaction 5162 5171	diarrhea.
T123	indication 5231 5236	NSCLC
T125	adversereaction 5241 5247	anemia
T127	adversereaction 5249 5260	neutropenia
T129	adversereaction 5262 5278	thrombocytopenia
T131	adversereaction 5280 5288	alopecia
T133	adversereaction 5290 5311	peripheral neuropathy
T135	adversereaction 5313 5319	nausea
T137	adversereaction 5325 5333	fatigue.
T139	tradename 5393 5401	ABRAXANE
T141	indication 5405 5435	adenocarcinoma of the pancreas
T143	adversereaction 5440 5451	neutropenia
T145	adversereaction 5453 5460	fatigue
T147	adversereaction 5462 5483	peripheral neuropathy
T149	adversereaction 5485 5491	nausea
T151	adversereaction 5493 5501	alopecia
T153	adversereaction 5503 5519	peripheral edema
T155	adversereaction 5521 5529	diarrhea
T157	adversereaction 5531 5538	pyrexia
T159	adversereaction 5540 5548	vomiting
T161	adversereaction 5550 5568	decreased appetite
T163	adversereaction 5570 5574	rash
T165	adversereaction 5580 5592	dehydration.
T167	company 5647 5666	Celgene Corporation
T169	tradename 5864 5872	ABRAXANE
T171	indication 6128 6152	Metastatic Breast Cancer
T173	indication 6159 6185	Non-Small Cell Lung Cancer
T175	indication 6192 6222	Adenocarcinoma of the Pancreas
T177	indication 6260 6284	Metastatic Breast Cancer
T179	indication 6292 6318	Non-Small Cell Lung Cancer
T181	indication 6325 6355	Adenocarcinoma of the Pancreas
T183	routeofadministration 6531 6542	Intravenous
T185	corecomposition 6787 6794	Albumin
T187	indication 6904 6928	Metastatic Breast Cancer
T189	indication 6966 6992	Non-Small Cell Lung Cancer
T191	indication 7029 7059	Adenocarcinoma of the Pancreas
T193	tradename 7098 7106	ABRAXANE
T195	activeingredient 7117 7127	Paclitaxel
T197	indication 7601 7625	Metastatic Breast Cancer
T199	indication 7634 7660	Non-Small Cell Lung Cancer
T201	indication 7669 7699	Adenocarcinoma of the Pancreas
T203	tradename 8002 8010	ABRAXANE
T205	nanoparticle 8039 8073	paclitaxel protein-bound particles
T207	corecomposition 8102 8115	albumin-bound
T209	tradename 8158 8166	ABRAXANE
T211	tradename 8485 8493	ABRAXANE
T213	corecomposition 8604 8611	albumin
T215	activeingredient 8620 8630	paclitaxel
T217	activeingredient 8762 8772	PACLITAXEL
T219	indication 8819 8843	Metastatic Breast Cancer
T221	tradename 8844 8852	ABRAXANE
T223	indication 9113 9139	Non-Small Cell Lung Cancer
T225	tradename 9140 9148	ABRAXANE
T227	indication 9214 9251	metastatic non-small cell lung cancer
T229	indication 9369 9399	Adenocarcinoma of the Pancreas
T231	tradename 9400 9408	ABRAXANE
T233	indication 9468 9509	metastatic adenocarcinoma of the pancreas
T235	indication 9580 9604	Metastatic Breast Cancer
T237	indication 9651 9675	metastatic breast cancer
T239	tradename 9757 9765	ABRAXANE
T241	dose 9769 9778	260 mg/m2
T243	routeofadministration 9792 9805	intravenously
T245	frequency 9822 9836	every 3 weeks.
T247	indication 9843 9869	Non-Small Cell Lung Cancer
T249	tradename 9894 9902	ABRAXANE
T251	dose 9906 9915	100 mg/m2
T253	routeofadministration 9935 9946	intravenous
T255	tradename 10088 10096	ABRAXANE
T257	indication 10134 10164	Adenocarcinoma of the Pancreas
T259	tradename 10189 10197	ABRAXANE
T261	dose 10201 10210	125 mg/m2
T263	routeofadministration 10230 10241	intravenous
T265	tradename 10355 10363	ABRAXANE
T267	tradename 10748 10756	ABRAXANE
T269	indication 10774 10815	metastatic adenocarcinoma of the pancreas
T271	tradename 10883 10891	ABRAXANE
T273	tradename 11281 11289	ABRAXANE
T275	indication 11298 11307	MBC NSCLC
T277	indication 11683 11686	MBC
T279	indication 11689 11713	Metastatic Breast Cancer
T281	indication 11715 11720	NSCLC
T283	indication 11723 11750	Non-Small Cell Lung Cancer.
T285	dose 11942 11951	260 mg/m2
T287	indication 11970 11994	metastatic breast cancer
T289	dose 11998 12007	100 mg/m2
T291	indication 12026 12052	non-small cell lung cancer
T293	tradename 12342 12342	
T295	indication 12342 12366	Metastatic Breast Cancer
T297	adversereaction 12391 12409	severe neutropenia
T299	tradename 12505 12513	ABRAXANE
T301	dose 12552 12561	220 mg/m2
T303	tradename 12588 12600	ABRAXANE. 
T305	adversereaction 12618 12636	severe neutropenia
T307	adversereaction 12640 12665	severe sensory neuropathy
T309	dose 12711 12720	180 mg/m2
T311	adversereaction 12728 12754	Grade 3 sensory neuropathy
T313	tradename 12863 12871	ABRAXANE
T315	tradename 12967 12968	 
T317	indication 12968 12994	Non-Small Cell Lung Cancer
T319	tradename 13014 13022	ABRAXANE
T321	tradename 13654 13662	ABRAXANE
T323	tradename 13719 13727	ABRAXANE
T325	adversereaction 13732 13764	Grade 3-4 peripheral neuropathy.
T327	tradename 13774 13782	ABRAXANE
T329	adversereaction 13835 13856	peripheral neuropathy
T331	indication 14060 14065	NSCLC
T333	tradename 14109 14117	ABRAXANE
T335	tradename 14641 14644	 
T337	indication 14644 14674	Adenocarcinoma of the Pancreas
T339	indication 14715 14745	adenocarcinoma of the pancreas
T341	indication 14855 14885	Adenocarcinoma of the Pancreas
T343	tradename 14899 14907	ABRAXANE
T345	indication 15161 15191	adenocarcinoma of the pancreas
T347	indication 15366 15396	Adenocarcinoma of the Pancreas
T349	tradename 15453 15461	ABRAXANE
T351	indication 16161 16191	adenocarcinoma of the pancreas
T353	indication 16297 16327	Adenocarcinoma of the Pancreas
T355	tradename 16351 16359	ABRAXANE
T357	tradename 16927 16936	 ABRAXANE
T359	activeingredient 16994 17004	paclitaxel
T361	tradename 17056 17067	ABRAXANE. 
T363	tradename 17104 17112	ABRAXANE
T365	activeingredient 17273 17283	paclitaxel
T367	tradename 17338 17346	ABRAXANE
T369	adversereaction 17482 17495	extravasation
T371	tradename 17630 17638	ABRAXANE
T373	adversereaction 17693 17719	infusion-related reactions
T375	adversereaction 17777 17803	hypersensitivity reactions
T377	tradename 17859 17871	ABRAXANE. 
T379	tradename 17960 17972	ABRAXANE. 
T381	tradename 18034 18042	ABRAXANE
T383	routeofadministration 18146 18157	Intravenous
T385	tradename 18175 18184	 ABRAXANE
T387	activeingredient 19207 19218	paclitaxel.
T389	tradename 19723 19731	ABRAXANE
T391	tradename 19979 19987	ABRAXANE
T393	tradename 20245 20253	ABRAXANE
T395	tradename 20528 20536	ABRAXANE
T397	tradename 21178 21186	ABRAXANE
T399	activeingredient 21539 21549	paclitaxel
T401	corecomposition 21564 21577	albumin-bound
T403	tradename 21650 21659	 ABRAXANE
T405	tradename 21816 21824	ABRAXANE
T407	tradename 21923 21924	 
T409	adversereaction 21924 21947	Bone marrow suppression
T411	adversereaction 21959 21971	neutropenia)
T413	tradename 22022 22034	ABRAXANE. 
T415	adversereaction 22055 22076	Grade 3-4 neutropenia
T417	indication 22110 22140	metastatic breast cancer (MBC)
T419	indication 22163 22197	non-small cell lung cancer (NSCLC)
T421	adversereaction 22256 22269	myelotoxicity
T423	indication 22363 22367	MBC)
T425	indication 22395 22400	NSCLC
T427	indication 22409 22427	pancreatic cancer)
T429	tradename 22449 22457	ABRAXANE
T431	tradename 22645 22653	ABRAXANE
T433	tradename 22682 22690	ABRAXANE
T435	indication 22737 22740	MBC
T437	indication 22744 22750	NSCLC.
T439	indication 22769 22772	MBC
T441	tradename 22819 22827	ABRAXANE
T443	indication 22953 22958	NSCLC
T445	tradename 23078 23086	ABRAXANE
T447	indication 23393 23423	adenocarcinoma of the pancreas
T449	tradename 23434 23442	ABRAXANE
T451	tradename 23817 23818	 
T453	adversereaction 23818 23836	Sensory neuropathy
T455	adversereaction 23929 23960	Grade 1 or 2 sensory neuropathy
T457	adversereaction 24021 24047	Grade 3 sensory neuropathy
T459	tradename 24067 24075	ABRAXANE
T461	indication 24123 24147	metastatic breast cancer
T463	indication 24192 24197	NSCLC
T465	tradename 24279 24287	ABRAXANE
T467	adversereaction 24333 24339	Sepsis
T469	tradename 24341 24342	 
T471	adversereaction 24342 24348	Sepsis
T473	adversereaction 24392 24403	neutropenia
T475	tradename 24417 24425	ABRAXANE
T477	co-administereddrug 24446 24458	gemcitabine.
T479	adversereaction 24665 24684	febrile neutropenia
T481	tradename 24696 24704	ABRAXANE
T483	co-administereddrug 24709 24720	gemcitabine
T485	adversereaction 24855 24866	Pneumonitis
T487	tradename 24868 24869	 
T489	adversereaction 24869 24880	Pneumonitis
T491	tradename 24957 24965	ABRAXANE
T493	co-administereddrug 24986 24998	gemcitabine.
T495	adversereaction 25043 25054	pneumonitis
T497	tradename 25069 25077	ABRAXANE
T499	co-administereddrug 25082 25093	gemcitabine
T501	adversereaction 25125 25137	pneumonitis.
T503	adversereaction 25208 25219	pneumonitis
T505	tradename 25260 25268	ABRAXANE
T507	co-administereddrug 25273 25285	gemcitabine.
T509	adversereaction 25292 25308	Hypersensitivity
T511	adversereaction 25338 25364	hypersensitivity reactions
T513	adversereaction 25376 25398	anaphylactic reactions
T515	adversereaction 25455 25480	hypersensitivity reaction
T517	tradename 25484 25492	ABRAXANE
T519	activeingredient 25601 25611	paclitaxel
T521	tradename 25672 25680	ABRAXANE
T523	tradename 25948 25956	ABRAXANE
T525	tradename 26060 26068	ABRAXANE
T527	indication 26105 26146	metastatic adenocarcinoma of the pancreas
T529	corecomposition 26458 26465	Albumin
T531	tradename 26475 26484	 ABRAXANE
T533	corecomposition 26494 26501	albumin
T535	corecomposition 26892 26900	albumin.
T537	tradename 26925 26934	 ABRAXANE
T539	activeingredient 27015 27025	paclitaxel
T541	corecomposition 27040 27053	albumin-bound
T543	tradename 27393 27405	ABRAXANE. 
T545	tradename 27670 27678	ABRAXANE
T547	tradename 27799 27807	ABRAXANE
T549	tradename 28208 28216	ABRAXANE
T551	indication 28220 28244	metastatic breast cancer
T553	adversereaction 28249 28257	alopecia
T555	adversereaction 28259 28270	neutropenia
T557	adversereaction 28272 28290	sensory neuropathy
T559	adversereaction 28292 28304	abnormal ECG
T561	adversereaction 28306 28322	fatigue/asthenia
T563	adversereaction 28324 28342	myalgia/arthralgia
T565	adversereaction 28344 28357	AST elevation
T567	adversereaction 28359 28389	alkaline phosphatase elevation
T569	adversereaction 28391 28397	anemia
T571	adversereaction 28399 28405	nausea
T573	adversereaction 28407 28417	infections
T575	adversereaction 28423 28431	diarrhea
T577	tradename 28516 28524	ABRAXANE
T579	co-administereddrug 28545 28556	carboplatin
T581	indication 28561 28587	non-small cell lung cancer
T583	adversereaction 28592 28598	anemia
T585	adversereaction 28600 28611	neutropenia
T587	adversereaction 28613 28629	thrombocytopenia
T589	adversereaction 28631 28639	alopecia
T591	adversereaction 28641 28662	peripheral neuropathy
T593	adversereaction 28664 28670	nausea
T595	adversereaction 28676 28683	fatigue
T597	tradename 28760 28768	ABRAXANE
T599	co-administereddrug 28789 28800	carboplatin
T601	indication 28805 28831	non-small cell lung cancer
T603	adversereaction 28836 28842	anemia
T605	adversereaction 28852 28861	pneumonia
T607	tradename 28946 28954	ABRAXANE
T609	adversereaction 28959 28970	neutropenia
T611	adversereaction 28977 28993	thrombocytopenia
T613	adversereaction 29004 29025	peripheral neuropathy
T615	tradename 29099 29107	ABRAXANE
T617	adversereaction 29112 29123	neutropenia
T619	adversereaction 29131 29147	thrombocytopenia
T621	adversereaction 29159 29165	anemia
T623	tradename 29243 29251	ABRAXANE
T625	adversereaction 29263 29274	neutropenia
T627	adversereaction 29282 29298	thrombocytopenia
T629	adversereaction 29310 29316	anemia
T631	tradename 29361 29369	ABRAXANE
T633	co-administereddrug 29390 29401	gemcitabine
T635	indication 29406 29431	pancreatic adenocarcinoma
T637	tradename 29562 29570	ABRAXANE
T639	adversereaction 29575 29586	neutropenia
T641	adversereaction 29588 29595	fatigue
T643	adversereaction 29597 29618	peripheral neuropathy
T645	adversereaction 29620 29626	nausea
T647	adversereaction 29628 29636	alopecia
T649	adversereaction 29638 29654	peripheral edema
T651	adversereaction 29656 29664	diarrhea
T653	adversereaction 29666 29673	pyrexia
T655	adversereaction 29675 29683	vomiting
T657	adversereaction 29685 29703	decreased appetite
T659	adversereaction 29705 29709	rash
T661	adversereaction 29715 29727	dehydration.
T663	tradename 29774 29782	ABRAXANE
T665	adversereaction 29825 29832	pyrexia
T667	adversereaction 29839 29850	dehydration
T669	adversereaction 29857 29866	pneumonia
T671	adversereaction 29876 29884	vomiting
T673	tradename 29968 29976	ABRAXANE
T675	adversereaction 29981 30002	peripheral neuropathy
T677	adversereaction 30009 30016	fatigue
T679	adversereaction 30026 30042	thrombocytopenia
T681	tradename 30115 30123	ABRAXANE
T683	adversereaction 30128 30139	neutropenia
T685	adversereaction 30150 30171	peripheral neuropathy
T687	tradename 30248 30256	ABRAXANE
T689	adversereaction 30268 30279	neutropenia
T691	adversereaction 30287 30303	thrombocytopenia
T693	adversereaction 30311 30318	fatigue
T695	adversereaction 30325 30346	peripheral neuropathy
T697	adversereaction 30354 30360	anemia
T699	adversereaction 30370 30378	diarrhea
T701	indication 30422 30446	Metastatic Breast Cancer
T703	tradename 30590 30598	ABRAXANE
T705	activeingredient 30602 30612	paclitaxel
T707	indication 30644 30669	metastatic breast cancer.
T709	tradename 30840 30850	ABRAXANE 
T711	tradename 30881 30881	
T713	activeingredient 30881 30891	Paclitaxel
T715	adversereaction 30945 30956	Neutropenia
T717	tradename 31016 31017	 
T719	adversereaction 31017 31033	Thrombocytopenia
T721	tradename 31093 31094	 
T723	adversereaction 31094 31100	Anemia
T725	tradename 31144 31145	 
T727	adversereaction 31145 31155	Infections
T729	tradename 31165 31165	
T731	adversereaction 31165 31184	Febrile Neutropenia
T733	tradename 31192 31192	
T735	adversereaction 31192 31210	Neutropenic Sepsis
T737	tradename 31224 31224	
T739	adversereaction 31224 31232	Bleeding
T741	indication 31324 31341	Metastatic Breast
T743	tradename 31343 31343	
T745	indication 31343 31349	Cancer
T747	tradename 31419 31429	ABRAXANE 
T749	dose 31429 31438	260 mg/m2
T751	tradename 31460 31460	
T753	activeingredient 31460 31470	Paclitaxel
T755	dose 31481 31490	175 mg/m2
T757	tradename 31510 31511	 
T759	adversereaction 31511 31538	Hypersensitivity Reaction c
T761	tradename 31627 31627	
T763	adversereaction 31627 31638	Bradycardia
T765	tradename 31657 31657	
T767	adversereaction 31657 31668	Hypotension
T769	tradename 31676 31677	 
T771	adversereaction 31677 31705	Severe Cardiovascular Events
T773	adversereaction 31712 31724	Abnormal ECG
T775	adversereaction 31797 31802	Cough
T777	tradename 31810 31810	
T779	adversereaction 31810 31817	Dyspnea
T781	tradename 31825 31825	
T783	adversereaction 31825 31843	Sensory Neuropathy
T785	tradename 31889 31889	
T787	adversereaction 31889 31896	Myalgia
T789	adversereaction 31899 31909	Arthralgia
T791	tradename 31954 31954	
T793	adversereaction 31954 31962	Asthenia
T795	tradename 32007 32007	
T797	adversereaction 32007 32028	Fluid Retention/Edema
T799	adversereaction 32093 32099	Nausea
T801	tradename 32161 32161	
T803	adversereaction 32161 32169	Vomiting
T805	tradename 32217 32217	
T807	adversereaction 32217 32225	Diarrhea
T809	tradename 32280 32280	
T811	adversereaction 32280 32289	Mucositis
T813	tradename 32342 32342	
T815	adversereaction 32342 32350	Alopecia
T817	adversereaction 32399 32419	Bilirubin Elevations
T819	tradename 32427 32427	
T821	adversereaction 32427 32458	Alkaline Phosphatase Elevations
T823	tradename 32499 32499	
T825	adversereaction 32499 32522	Injection Site Reaction
T827	activeingredient 32632 32642	Paclitaxel
T829	adversereaction 32734 32750	hypersensitivity
T831	adversereaction 32758 32766	flushing
T833	adversereaction 32768 32775	dyspnea
T835	adversereaction 32777 32787	chest pain
T837	adversereaction 32789 32801	hypotension)
T839	tradename 32960 32961	 
T841	adversereaction 32961 32972	Neutropenia
T843	indication 33030 33054	metastatic breast cancer
T845	dose 33182 33191	260 mg/m2
T847	activeingredient 33230 33240	paclitaxel
T849	dose 33264 33273	175 mg/m2
T851	tradename 33277 33277	
T853	adversereaction 33277 33289	Pancytopenia
T855	tradename 33438 33450	ABRAXANE. 
T857	tradename 33647 33655	ABRAXANE
T859	tradename 33782 33790	ABRAXANE
T861	activeingredient 33845 33855	paclitaxel
T863	corecomposition 33875 33882	albumin
T865	tradename 34258 34266	ABRAXANE
T867	tradename 35210 35221	ABRAXANE. 
T869	tradename 35351 35359	ABRAXANE
T871	tradename 35442 35450	ABRAXANE
T873	tradename 35619 35627	ABRAXANE
T875	tradename 36036 36044	ABRAXANE
T877	tradename 36350 36358	ABRAXANE
T879	tradename 36494 36502	ABRAXANE
T881	activeingredient 36536 36546	paclitaxel
T883	indication 37005 37031	Non-Small Cell Lung Cancer
T885	tradename 37071 37080	ABRAXANE/
T887	activeingredient 37117 37127	paclitaxel
T889	indication 37260 37294	non-small cell lung cancer (NSCLC)
T891	tradename 37345 37353	ABRAXANE
T893	routeofadministration 37377 37388	intravenous
T895	dose 37427 37436	100 mg/m2
T897	tradename 37482 37482	
T899	activeingredient 37482 37492	Paclitaxel
T901	routeofadministration 37526 37537	intravenous
T903	dose 37573 37582	200 mg/m2
T905	routeofadministration 37701 37714	intravenously
T907	tradename 37765 37774	ABRAXANE/
T909	activeingredient 37774 37784	paclitaxel
T911	activeingredient 37815 37825	paclitaxel
T913	tradename 38311 38319	ABRAXANE
T915	activeingredient 38331 38341	paclitaxel
T917	tradename 38565 38573	ABRAXANE
T919	tradename 38806 38814	ABRAXANE
T921	activeingredient 38852 38862	paclitaxel
T923	tradename 39088 39096	ABRAXANE
T925	dose 39098 39107	100 mg/m2
T927	frequency 39108 39115	weekly)
T929	tradename 39134 39134	
T931	activeingredient 39134 39144	Paclitaxel
T933	dose 39156 39165	200 mg/m2
T935	frequency 39166 39180	every 3 weeks)
T937	tradename 39368 39377	ABRAXANE/
T939	activeingredient 39430 39440	paclitaxel
T941	activeingredient 39505 39515	paclitaxel
T943	tradename 39761 39769	ABRAXANE
T945	activeingredient 39848 39858	paclitaxel
T947	tradename 40094 40102	ABRAXANE
T949	dose 40104 40113	100 mg/m2
T951	frequency 40114 40121	weekly)
T953	tradename 40145 40145	
T955	activeingredient 40145 40155	Paclitaxel
T957	dose 40167 40176	200 mg/m2
T959	frequency 40177 40191	every 3 weeks)
T961	tradename 40726 40734	ABRAXANE
T963	tradename 41007 41019	ABRAXANE.  
T965	indication 41053 41083	Adenocarcinoma of the Pancreas
T967	tradename 41146 41154	ABRAXANE
T969	indication 41255 41296	metastatic adenocarcinoma of the pancreas
T971	tradename 41440 41449	ABRAXANE/
T973	tradename 41603 41612	ABRAXANE/
T975	tradename 41704 41712	ABRAXANE
T977	tradename 41914 41922	ABRAXANE
T979	tradename 42123 42132	ABRAXANE/
T981	tradename 42149 42158	ABRAXANE(
T983	dose 42158 42168	125 mg/m2)
T985	tradename 42344 42353	ABRAXANE/
T987	tradename 42459 42468	ABRAXANE/
T989	tradename 42566 42575	ABRAXANE/
T991	tradename 42769 42777	ABRAXANE
T993	tradename 42994 43003	ABRAXANE/
T995	tradename 43056 43065	 ABRAXANE
T997	dose 43067 43077	125 mg/m2)
T999	tradename 44680 44689	ABRAXANE/
T1001	tradename 44755 44763	ABRAXANE
T1003	dose 44765 44775	125 mg/m2)
T1005	indication 45348 45378	adenocarcinoma of the pancreas
T1007	tradename 45392 45401	ABRAXANE/
T1009	tradename 45708 45717	ABRAXANE/
T1011	tradename 45918 45926	ABRAXANE
T1013	tradename 45965 45973	ABRAXANE
T1015	tradename 46085 46101	ABRAXANE-treated
T1017	tradename 46159 46167	ABRAXANE
T1019	tradename 46244 46253	ABRAXANE/
T1021	tradename 46537 46546	ABRAXANE/
T1023	tradename 46643 46651	ABRAXANE
T1025	tradename 46716 46724	ABRAXANE
T1027	activeingredient 46735 46745	Paclitaxel
T1029	tradename 46896 46907	ABRAXANE. 
T1031	activeingredient 47158 47168	paclitaxel
T1033	tradename 47209 47221	ABRAXANE.  
T1035	tradename 47327 47336	ABRAXANE.
T1037	tradename 47349 47357	ABRAXANE
T1039	activeingredient 47412 47422	paclitaxel
T1041	corecomposition 47442 47449	albumin
T1043	tradename 47605 47614	ABRAXANE.
T1045	tradename 47868 47876	ABRAXANE
T1047	activeingredient 48049 48059	paclitaxel
T1049	tradename 48107 48118	ABRAXANE. 
T1051	activeingredient 48364 48374	paclitaxel
T1053	tradename 48456 48467	ABRAXANE. 
T1055	tradename 48564 48572	ABRAXANE
T1057	activeingredient 48833 48843	paclitaxel
T1059	tradename 48885 48893	ABRAXANE
T1061	tradename 49050 49058	ABRAXANE
T1063	activeingredient 49211 49221	paclitaxel
T1065	tradename 49364 49376	ABRAXANE. 
T1067	tradename 49455 49463	ABRAXANE
T1069	activeingredient 49674 49684	paclitaxel
T1071	activeingredient 49763 49773	paclitaxel
T1073	activeingredient 49970 49980	paclitaxel
T1075	tradename 50197 50209	ABRAXANE. 
T1077	activeingredient 50566 50576	paclitaxel
T1079	tradename 50653 50661	ABRAXANE
T1081	activeingredient 50712 50722	paclitaxel
T1083	activeingredient 50928 50938	paclitaxel
T1085	tradename 51023 51031	ABRAXANE
T1087	tradename 51524 51536	ABRAXANE. 
T1089	tradename 51594 51602	ABRAXANE
T1091	tradename 51928 51939	ABRAXANE. 
T1093	activeingredient 51957 51967	paclitaxel
T1095	corecomposition 51982 51995	albumin-bound
T1097	dose 52070 52077	6 mg/m2
T1099	dose 52611 52618	3 mg/m2
T1101	activeingredient 52748 52758	paclitaxel
T1103	tradename 52787 52787	
T1105	activeingredient 52787 52797	Paclitaxel
T1107	tradename 53184 53192	ABRAXANE
T1109	tradename 53316 53324	ABRAXANE
T1111	indication 53346 53370	metastatic breast cancer
T1113	tradename 53519 53530	ABRAXANE. 
T1115	tradename 53587 53595	ABRAXANE
T1117	indication 53644 53670	non-small cell lung cancer
T1119	tradename 54114 54122	ABRAXANE
T1121	tradename 54565 54573	ABRAXANE
T1123	activeingredient 54797 54807	paclitaxel
T1125	tradename 54914 54922	ABRAXANE
T1127	tradename 55013 55021	ABRAXANE
T1129	indication 55229 55270	metastatic adenocarcinoma of the pancreas
T1131	tradename 55422 55430	ABRAXANE
T1133	tradename 55827 55835	ABRAXANE
T1135	tradename 55999 56008	 ABRAXANE
T1137	nanoparticle 56036 56070	paclitaxel protein-bound particles
T1139	corecomposition 56099 56112	albumin-bound
T1141	nanoparticle 56117 56169	paclitaxel formulated as albumin-bound nanoparticles
T1143	particlediameter 56213 56228	130 nanometers.
T1145	tradename 56229 56229	
T1147	activeingredient 56229 56239	Paclitaxel
T1149	tradename 56304 56312	ABRAXANE
T1151	inactiveingredient 56413 56428	Sodium Chloride
T1153	routeofadministration 56453 56464	intravenous
T1155	activeingredient 56516 56526	paclitaxel
T1157	corecomposition 56543 56551	albumin)
T1159	corecomposition 56586 56593	albumin
T1161	inactiveingredient 56606 56622	sodium caprylate
T1163	inactiveingredient 56627 56654	sodium acetyltryptophanate)
T1165	nanoparticle 56720 56769	paclitaxel formulated as albumin-bound particles.
T1167	tradename 56770 56778	ABRAXANE
T1169	tradename 56821 56829	ABRAXANE
T1171	activeingredient 56833 56843	paclitaxel
T1173	chemoclass 56847 56869	microtubule inhibitor.
T1175	activeingredient 56894 56904	paclitaxel
T1177	activeingredient 56908 56909	5
T1179	activeingredient 56912 56917	20- 1
T1181	activeingredient 56918 56919	2
T1183	activeingredient 56922 56923	4
T1185	activeingredient 56924 56925	7
T1187	activeingredient 56928 56930	10
T1189	activeingredient 56933 56966	13 -hexahydroxytax-11-en-9-one 4
T1191	activeingredient 56967 57008	10-diacetate 2-benzoate 13-ester with (2R
T1193	activeingredient 57009 57052	3S)-N-benzoyl-3-phenylisoserine. Paclitaxel
T1195	tradename 57092 57092	
T1197	activeingredient 57092 57102	Paclitaxel
T1199	activeingredient 57173 57183	C47H51NO14
T1201	molecularweight 57210 57217	853.91.
T1203	tradename 57362 57371	 ABRAXANE
T1205	chemoclass 57377 57398	microtubule inhibitor
T1207	tradename 57701 57701	
T1209	activeingredient 57701 57711	Paclitaxel
T1211	activeingredient 57910 57920	paclitaxel
T1213	tradename 57962 57970	ABRAXANE
T1215	dose 57989 58004	80 to 375 mg/m2
T1217	activeingredient 58080 58090	paclitaxel
T1219	tradename 58094 58105	ABRAXANE. 
T1221	routeofadministration 58115 58126	intravenous
T1223	tradename 58145 58153	ABRAXANE
T1225	activeingredient 58155 58165	paclitaxel
T1227	dose 58441 58456	80 to 300 mg/m2
T1229	activeingredient 58485 58495	paclitaxel
T1231	tradename 58500 58508	ABRAXANE
T1233	routeofadministration 58545 58556	intravenous
T1235	dose 58602 58611	260 mg/m2
T1237	tradename 58612 58620	ABRAXANE
T1239	dose 58700 58709	175 mg/m2
T1241	activeingredient 58710 58720	paclitaxel
T1243	tradename 58835 58843	ABRAXANE
T1245	activeingredient 58853 58863	paclitaxel
T1247	tradename 58949 58957	ABRAXANE
T1249	activeingredient 59004 59014	paclitaxel
T1251	activeingredient 59174 59184	paclitaxel
T1253	tradename 59225 59233	ABRAXANE
T1255	activeingredient 59265 59275	paclitaxel
T1257	activeingredient 59346 59356	paclitaxel
T1259	tradename 59362 59370	ABRAXANE
T1261	activeingredient 59399 59409	paclitaxel
T1263	activeingredient 59510 59520	paclitaxel
T1265	activeingredient 59688 59699	paclitaxel.
T1267	volumeofdistribution 59751 59757	1741 L
T1269	activeingredient 59864 59875	paclitaxel.
T1271	activeingredient 59963 59973	paclitaxel
T1273	activeingredient 60150 60160	paclitaxel
T1275	activeingredient 60636 60646	paclitaxel
T1277	dose 60859 60874	80 to 300 mg/m2
T1279	activeingredient 60904 60914	paclitaxel
T1281	clearance 60927 60942	13 to 30 L/h/m2
T1283	plasmahalflife 60988 61003	13 to 27 hours.
T1285	dose 61035 61044	260 mg/m2
T1287	tradename 61054 61062	ABRAXANE
T1289	activeingredient 61515 61525	paclitaxel
T1291	tradename 61536 61544	ABRAXANE
T1293	activeingredient 61791 61802	paclitaxel.
T1295	activeingredient 62039 62049	paclitaxel
T1297	activeingredient 62089 62099	paclitaxel
T1299	activeingredient 62304 62314	paclitaxel
T1301	tradename 62617 62625	ABRAXANE
T1303	indication 62743 62784	metastatic adenocarcinoma of the pancreas
T1305	activeingredient 63105 63115	paclitaxel
T1307	tradename 63126 63134	ABRAXANE
T1309	activeingredient 63344 63354	paclitaxel
T1311	tradename 63464 63472	ABRAXANE
T1313	activeingredient 63738 63749	paclitaxel.
T1315	tradename 63789 63797	ABRAXANE
T1317	tradename 63884 63892	ABRAXANE
T1319	indication 63919 63924	NSCLC
T1321	activeingredient 63972 63982	paclitaxel
T1323	activeingredient 64199 64210	paclitaxel.
T1325	tradename 64250 64258	ABRAXANE
T1327	tradename 64312 64320	ABRAXANE
T1329	tradename 64490 64498	ABRAXANE
T1331	tradename 64522 64522	
T1333	activeingredient 64522 64532	Paclitaxel
T1335	tradename 64645 64653	ABRAXANE
T1337	activeingredient 64746 64756	paclitaxel
T1339	corecomposition 64771 64784	albumin-bound
T1341	dose 65215 65229	3 and 12 mg/m2
T1343	frequency 65229 65234	/week
T1345	activeingredient 65443 65453	paclitaxel
T1347	corecomposition 65468 65481	albumin-bound
T1349	dose 65551 65559	54 mg/m2
T1351	dose 65575 65584	175 mg/m2
T1353	indication 65623 65647	Metastatic Breast Cancer
T1355	tradename 65818 65826	ABRAXANE
T1357	indication 65830 65855	metastatic breast cancer.
T1359	tradename 65904 65912	ABRAXANE
T1361	dose 65967 65976	175 mg/m2
T1363	indication 65997 66022	metastatic breast cancer.
T1365	dose 66060 66069	300 mg/m2
T1367	indication 66114 66139	metastatic breast cancer.
T1369	indication 66332 66357	metastatic breast cancer.
T1371	tradename 66396 66404	ABRAXANE
T1373	dose 66418 66427	260 mg/m2
T1375	activeingredient 66462 66472	paclitaxel
T1377	dose 66486 66495	175 mg/m2
T1379	tradename 67101 67109	ABRAXANE
T1381	activeingredient 67330 67340	paclitaxel
T1383	indication 67525 67549	Metastatic Breast Cancer
T1385	tradename 67557 67566	 ABRAXANE
T1387	dose 67567 67576	260 mg/m2
T1389	tradename 67578 67578	
T1391	activeingredient 67578 67588	Paclitaxel
T1393	dose 67599 67608	175 mg/m2
T1395	indication 68583 68609	Non-Small Cell Lung Cancer
T1397	indication 68718 68744	non-small cell lung cancer
T1399	tradename 68756 68764	ABRAXANE
T1401	activeingredient 68800 68810	paclitaxel
T1403	indication 68903 68930	non-small cell lung cancer.
T1405	tradename 68933 68941	ABRAXANE
T1407	routeofadministration 68965 68976	intravenous
T1409	dose 69015 69024	100 mg/m2
T1411	tradename 69070 69070	
T1413	activeingredient 69070 69080	Paclitaxel
T1415	routeofadministration 69114 69125	intravenous
T1417	dose 69161 69170	200 mg/m2
T1419	routeofadministration 69289 69302	intravenously
T1421	tradename 69353 69362	ABRAXANE/
T1423	activeingredient 69362 69372	paclitaxel
T1425	tradename 69963 69972	ABRAXANE/
T1427	activeingredient 70079 70089	paclitaxel
T1429	indication 70293 70319	Non-Small Cell Lung Cancer
T1431	tradename 70356 70365	 ABRAXANE
T1433	dose 70367 70376	100 mg/m2
T1435	frequency 70377 70384	weekly)
T1437	tradename 70408 70408	
T1439	activeingredient 70408 70418	Paclitaxel
T1441	dose 70430 70439	200 mg/m2
T1443	frequency 70440 70454	every 3 weeks)
T1445	indication 70970 71000	Adenocarcinoma of the Pancreas
T1447	tradename 71102 71110	ABRAXANE
T1449	indication 71186 71228	metastatic adenocarcinoma of the pancreas.
T1451	tradename 71868 71877	ABRAXANE/
T1453	tradename 72160 72169	ABRAXANE/
T1455	tradename 72190 72198	ABRAXANE
T1457	dose 72199 72208	125 mg/m2
T1459	routeofadministration 72215 72226	intravenous
T1461	dose 72279 72289	1000 mg/m2
T1463	routeofadministration 72296 72307	intravenous
T1465	dose 72425 72435	1000 mg/m2
T1467	routeofadministration 72442 72453	intravenous
T1469	dose 72553 72563	1000 mg/m2
T1471	indication 73601 73631	Adenocarcinoma of the Pancreas
T1473	tradename 73650 73660	 ABRAXANE(
T1475	dose 73660 73670	125 mg/m2)
T1477	tradename 74288 74296	ABRAXANE
T1479	activeingredient 75997 76007	paclitaxel
T1481	tradename 76635 76643	ABRAXANE
T1483	tradename 76835 76843	ABRAXANE
T1485	tradename 76971 76979	ABRAXANE
T1487	tradename 77451 77459	ABRAXANE
T1489	tradename 77708 77716	ABRAXANE
T1491	company 78079 78098	Celgene Corporation
T1493	tradename 78118 78126	ABRAXANE
T1495	company 78157 78175	Abraxis BioScience
T1497	company 78177 78181	LLC.
T1499	company 78194 78212	Abraxis BioScience
T1501	company 78214 78218	LLC.
T1503	tradename 78242 78242	
T1505	company 78242 78260	Abraxis BioScience
T1507	company 78262 78265	LLC
T1509	company 78298 78318	Celgene Corporation.
T1511	tradename 78437 78447	 ABRAXANE
T1513	activeingredient 78466 78476	paclitaxel
T1515	corecomposition 78530 78543	albumin-bound
T1517	tradename 78603 78611	ABRAXANE
T1519	tradename 78764 78783	ABRAXANE? ABRAXANE
T1521	indication 78938 78964	non-small cell lung cancer
T1523	tradename 79206 79214	ABRAXANE
T1525	tradename 79273 79284	ABRAXANE? 
T1527	tradename 79299 79307	ABRAXANE
T1529	tradename 79413 79425	ABRAXANE.  
T1531	tradename 79471 79480	ABRAXANE?
T1533	tradename 79500 79508	ABRAXANE
T1535	tradename 79698 79716	ABRAXANE. ABRAXANE
T1537	tradename 79851 79859	ABRAXANE
T1539	tradename 79934 79945	ABRAXANE. 
T1541	tradename 80104 80115	ABRAXANE. 
T1543	tradename 80175 80183	ABRAXANE
T1545	tradename 80268 80276	ABRAXANE
T1547	tradename 80588 80599	ABRAXANE? 
T1549	tradename 80626 80634	ABRAXANE
T1551	tradename 80752 80761	ABRAXANE.
T1553	tradename 80830 80841	ABRAXANE. 
T1555	tradename 80878 80886	ABRAXANE
T1557	tradename 80914 80922	ABRAXANE
T1559	routeofadministration 80947 80958	intravenous
T1561	tradename 81045 81056	ABRAXANE. 
T1563	tradename 81094 81114	ABRAXANE? ABRAXANE
T1565	tradename 81188 81196	ABRAXANE
T1567	tradename 81458 81466	ABRAXANE
T1569	tradename 81628 81636	ABRAXANE
T1571	tradename 81879 81887	ABRAXANE
T1573	tradename 82132 82140	ABRAXANE
T1575	tradename 82211 82219	ABRAXANE
T1577	tradename 82870 82881	ABRAXANE. 
T1579	tradename 83103 83114	ABRAXANE. 
T1581	tradename 83297 83308	ABRAXANE. 
T1583	tradename 83425 83433	ABRAXANE
T1585	tradename 83549 83560	ABRAXANE? 
T1587	activeingredient 83579 83589	paclitaxel
T1589	corecomposition 83606 83614	albumin)
T1591	corecomposition 83641 83648	albumin
T1593	inactiveingredient 83661 83677	sodium caprylate
T1595	inactiveingredient 83682 83709	sodium acetyltryptophanate)
T1597	company 83843 83862	Celgene Corporation
T1599	tradename 83881 83889	ABRAXANE
T1601	company 83920 83938	Abraxis BioScience
T1603	company 83940 83944	LLC.
T1605	company 83957 83975	Abraxis BioScience
T1607	company 83977 83981	LLC.
T1609	tradename 84005 84005	
T1611	company 84005 84023	Abraxis BioScience
T1613	company 84025 84028	LLC
T1615	company 84061 84081	Celgene Corporation.
